Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Natera, Inc. (NASDAQ:NTRA) Co-Founder Sheena Jonathan, a director of Natera, Inc., sold 93 shares of common stock on July 21, 2025, at a price of $139.29, totaling $12953. The company, currently valued at $19.17 billion, has demonstrated strong revenue growth of 51.5% over the last twelve months. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
According to a Form 4 filing with the Securities and Exchange Commission, the sale was to cover tax obligations related to the vesting of Restricted Stock Units (RSUs). The transaction was executed under a pre-arranged trading plan that complies with Rule 10b5-1(c).
On July 20, 2025, Jonathan also exercised options to acquire 190 shares of Natera common stock upon the vesting of RSUs.
Following these transactions, Jonathan directly owns 245,801 shares of Natera common stock. Additionally, Jonathan indirectly owns 35,782 shares through the Caraluna 1 Trust and 35,782 shares through the Caraluna 2 Trust, but disclaims beneficial ownership of these shares. The company maintains a healthy financial position with a "GOOD" overall health score and operates with a moderate level of debt, as revealed by InvestingPro’s detailed analysis.
In other recent news, Natera Inc . reported its first-quarter 2025 earnings, surpassing analysts’ expectations with an earnings per share of -$0.50, compared to the forecast of -$0.64. The company’s revenue reached $522 million, representing a 37% increase year-over-year. Additionally, Medicare has expanded coverage for Natera’s Signatera MRD assay to include a broader range of cancers, which could potentially boost future revenues. RBC Capital Markets maintained their Outperform rating on Natera, with a price target of $251, citing strong performance and increased revenue guidance as key factors. Similarly, TD Cowen raised their price target for Natera to $200, highlighting a 13% increase in sales, driven by growth in Signatera’s clinical volumes. Analysts from Leerink Partners also reiterated an Outperform rating, emphasizing recent Medicare coverage developments for Natera’s WGS Signatera assay. These announcements reflect a period of positive momentum for the company, with analysts expressing confidence in Natera’s financial projections for the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.